Use of CGF in Oral and Implant Surgery: From Laboratory Evidence to Clinical Evaluation.
Andrea PalermoLaura GiannottiBenedetta Di Chiara StancaFranco FerranteAntonio GnoniPaola NittiNadia CalabrisoChristian DemitriFabrizio DamianoTiziano BataniMassimo LungheriniMaria Annunziata CarluccioBiagio RaponeErda QorriAntonio ScaranoLuisa SiculellaEleonora StancaAlessio RochiraPublished in: International journal of molecular sciences (2022)
Edentulism is the condition of having lost natural teeth, and has serious social, psychological, and emotional consequences. The need for implant services in edentulous patients has dramatically increased during the last decades. In this study, the effects of concentrated growth factor (CGF), an autologous blood-derived biomaterial, in improving the process of osseointegration of dental implants have been evaluated. Here, permeation of dental implants with CGF has been obtained by using a Round up device. These CGF-coated dental implants retained a complex internal structure capable of releasing growth factors (VEGF, TGF-β1, and BMP-2) and matrix metalloproteinases (MMP-2 and MMP-9) over time. The CGF-permeated implants induced the osteogenic differentiation of human bone marrow stem cells (hBMSC) as confirmed by matrix mineralization and the expression of osteogenic differentiation markers. Moreover, CGF provided dental implants with a biocompatible and biologically active surface that significantly improved adhesion of endothelial cells on CGF-coated implants compared to control implants (without CGF). Finally, data obtained from surgical interventions with CGF-permeated dental implants presented better results in terms of optimal osseointegration and reduced post-surgical complications. These data, taken together, highlight new and interesting perspectives in the use of CGF in the dental implantology field to improve osseointegration and promote the healing process.
Keyphrases
- endothelial cells
- bone marrow
- stem cells
- growth factor
- mesenchymal stem cells
- soft tissue
- healthcare
- high glucose
- clinical evaluation
- primary care
- end stage renal disease
- minimally invasive
- ejection fraction
- electronic health record
- chronic kidney disease
- cell therapy
- poor prognosis
- vascular endothelial growth factor
- pseudomonas aeruginosa
- risk factors
- prognostic factors
- drug delivery
- big data
- escherichia coli
- drug induced
- cell migration
- depressive symptoms
- cystic fibrosis
- epithelial mesenchymal transition
- oxidative stress
- signaling pathway
- coronary artery bypass
- induced pluripotent stem cells